

Medicine summary - Antipsychotics- flupenthixol

| | | | Case Group | Death Outcomes | Sole |
|----------------|------------------------------------------------------|---------------------------------------------|------------|----------------|-----------|
| Case Count | | | 117 | 3 | 80 |
| Reaction Count | Blood and lymphatic system disorders | Anaemia | 1 | 0 | 0 |
| | | Pancytopenia | 1 | 0 | 1 |
| | | Splenomegaly | 1 | 0 | 0 |
| | | Eosinophilia | 2 | 0 | 1 |
| | | Leukocytosis | 1 | 0 | 0 |
| | | Leukopenia | 2 | 0 | 1 |
| | | Febrile neutropenia | 1 | 0 | 1 |
| | | Neutropenia | 3 | 0 | 0 |
| | | Blood and lymphatic system disorders | | 12 | 0 |
| | Cardiac disorders | Tachycardia | 1 | 0 | 0 |
| | | Myocardial ischaemia | 1 | 1 | 0 |
| | | Cardiomyopathy | 3 | 0 | 0 |
| | | Myocarditis | 1 | 0 | 0 |
| | | Cardiac disorders | | 6 | 1 |
| | Endocrine disorders | Hyperprolactinaemia | 1 | 0 | 0 |
| | | Endocrine disorders | | 1 | 0 |
| | Eye disorders | Periorbital oedema | 1 | 0 | 1 |
| | | Visual impairment | 2 | 0 | 1 |
| | | Eye disorders | | 3 | 0 |
| | Gastrointestinal disorders | Nausea | 3 | 0 | 2 |
| | | Vomiting | 2 | 0 | 1 |
| | | Salivary hypersecretion | 1 | 0 | 0 |
| | | Tongue oedema | 1 | 0 | 1 |
| | | Gastrointestinal disorders | | 7 | 0 |
| | General disorders and administration site conditions | Injection site abscess sterile | 1 | 0 | 1 |
| | | Injection site inflammation | 11 | 0 | 11 |
| | | Injection site pain | 4 | 0 | 4 |
| | | Injection site reaction | 32 | 0 | 32 |
| | | Pyrexia | 4 | 0 | 2 |
| Death | | 1 | 1 | 0 | |
| Asthenia | | 1 | 0 | 1 | |
| Fatigue | | 2 | 0 | 2 | |

 Outcome Description


 (Causality possible,Causality probable,Causality certain)

 Suspect Type

 Suspect Code


 Case Group


 GM


 Flupenthixol Decanoate


Medicine summary - Antipsychotics- flupenthixol


| Reaction Count | | | Case Group | Death Outcomes | Sole |
|------------------------------------|------------------------------------------------------|-------------------------------------------------------------|------------|----------------|-----------|
| | General disorders and administration site conditions | Malaise | 3 | 0 | 1 |
| | | Gait disturbance | 5 | 0 | 4 |
| | | Influenza like illness | 1 | 0 | 0 |
| | | Face oedema | 3 | 0 | 2 |
| | | Oedema | 4 | 0 | 4 |
| | | Chest pain | 1 | 0 | 0 |
| | | Pain | 3 | 0 | 3 |
| | | General disorders and administration site conditions | 76 | 1 | 67 |
| | Hepatobiliary disorders | Hepatic function abnormal | 2 | 0 | 0 |
| | | Hepatomegaly | 1 | 0 | 0 |
| | | Hepatic steatosis | 1 | 0 | 0 |
| | | Hepatobiliary disorders | 4 | 0 | 0 |
| | Immune system disorders | Anaphylactoid reaction | 2 | 0 | 2 |
| | | Immune system disorders | 2 | 0 | 2 |
| | Infections and infestations | Cellulitis | 2 | 0 | 2 |
| | | Injection site abscess | 2 | 0 | 2 |
| | | Upper respiratory tract infection | 1 | 0 | 0 |
| | | Cystitis | 1 | 0 | 1 |
| | | Infections and infestations | 6 | 0 | 5 |
| | Injury, poisoning and procedural complications | Toxicity to various agents | 1 | 1 | 0 |
| | | Overdose | 1 | 0 | 0 |
| | | Injury, poisoning and procedural complications | 2 | 1 | 0 |
| | Investigations | Blood creatine phosphokinase increased | 3 | 0 | 1 |
| | | Quality of life decreased | 2 | 0 | 2 |
| | | Weight decreased | 1 | 0 | 1 |
| | | Weight increased | 3 | 0 | 2 |
| | | Glomerular filtration rate decreased | 1 | 0 | 0 |
| | | Investigations | 10 | 0 | 6 |
| Metabolism and nutrition disorders | Decreased appetite | 1 | 0 | 1 | |
| | Hyponatraemia | 1 | 0 | 0 | |
| | Dehydration | 1 | 0 | 0 | |
| | Hypoproteinaemia | 1 | 0 | 0 | |

 Outcome Description


 (Causality possible,Causality probable,Causality certain)

 Suspect Type

 Suspect Code


 Case Group

 GM


 Flupenthixol Decanoate


Medicine summary - Antipsychotics- flupenthixol


| | | | Case Group | Death Outcomes | Sole |
|----------------|-------------------------------------------------|--------------------------------------------------------|---------------------------|----------------|-----------|
| Reaction Count | Metabolism and nutrition disorders | Metabolism and nutrition disorders | 4 | 0 | 1 |
| | Musculoskeletal and connective tissue disorders | Arthralgia | 1 | 0 | 0 |
| | | Joint stiffness | 1 | 0 | 0 |
| | | Muscle rigidity | 2 | 0 | 1 |
| | | Musculoskeletal stiffness | 3 | 0 | 3 |
| | | Pain in extremity | 1 | 0 | 1 |
| | | Musculoskeletal and connective tissue disorders | 8 | 0 | 5 |
| | | Nervous system disorders | Headache | 1 | 0 |
| | Mental impairment | | 1 | 0 | 1 |
| | Akathisia | | 5 | 0 | 4 |
| | Akinesia | | 1 | 0 | 1 |
| | Extrapyramidal disorder | | 7 | 0 | 4 |
| | Hyperkinesia | | 1 | 0 | 1 |
| | Tardive dyskinesia | | 6 | 0 | 4 |
| | Paralysis | | 1 | 0 | 1 |
| | Parkinsonism | | 1 | 0 | 1 |
| | Tremor | | 5 | 0 | 3 |
| | Ataxia | | 1 | 0 | 0 |
| | Lethargy | | 2 | 0 | 2 |
| | Syncope | | 1 | 0 | 1 |
| | Paraesthesia | | 1 | 0 | 0 |
| | Dysarthria | | 1 | 0 | 1 |
| | Speech disorder | | 2 | 0 | 1 |
| | Hypertonia | | 3 | 0 | 2 |
| | Neuroleptic malignant syndrome | | 3 | 0 | 1 |
| | Nervous system disorders | | 43 | 0 | 29 |
| | Pregnancy, puerperium and perinatal conditions | | Foetal growth restriction | 1 | 0 |
| | | Pregnancy, puerperium and perinatal conditions | 1 | 0 | 1 |
| | Psychiatric disorders | Agitation | 1 | 0 | 1 |
| | | Anxiety | 2 | 0 | 1 |
| | | Confusional state | 1 | 0 | 1 |
| | | Depression | 2 | 0 | 1 |

 Outcome Description


 (Causality possible,Causality probable,Causality certain)

 Suspect Type

 Suspect Code

 Case Group

 GM

 Flupenthixol Decanoate

Medicine summary - Antipsychotics- flupenthixol

| | | Case Group | Death Outcomes | Sole | |
|----------------|-------------------------------------------------|--------------------------------------------------------|----------------|----------|-----------|
| Reaction Count | Psychiatric disorders | Hallucination | 2 | 0 | 0 |
| | | Thinking abnormal | 1 | 0 | 1 |
| | | Anger | 1 | 0 | 1 |
| | | Elevated mood | 1 | 0 | 0 |
| | | Listless | 2 | 0 | 2 |
| | | Abnormal behaviour | 1 | 0 | 0 |
| | | Mental disorder | 1 | 0 | 1 |
| | | Psychotic disorder | 1 | 0 | 0 |
| | | Insomnia | 1 | 0 | 1 |
| | | Suicidal ideation | 2 | 0 | 1 |
| | | Suicide attempt | 2 | 0 | 0 |
| | | Psychiatric disorders | 21 | 0 | 11 |
| | Renal and urinary disorders | Nephrotic syndrome | 1 | 0 | 0 |
| | | Renal failure acute | 2 | 0 | 1 |
| | | Renal tubular necrosis | 1 | 0 | 0 |
| | | Urinary retention | 1 | 0 | 0 |
| | | Albuminuria | 1 | 0 | 0 |
| | | Renal and urinary disorders | 6 | 0 | 1 |
| | Reproductive system and breast disorders | Breast enlargement | 3 | 0 | 3 |
| | | Sexual dysfunction | 1 | 0 | 1 |
| | | Reproductive system and breast disorders | 4 | 0 | 4 |
| | Respiratory, thoracic and mediastinal disorders | Wheezing | 3 | 0 | 3 |
| | | Eosinophilic pneumonia | 1 | 0 | 1 |
| | | Pulmonary embolism | 1 | 1 | 0 |
| | | Dyspnoea | 5 | 0 | 4 |
| | | Hypoventilation | 1 | 0 | 0 |
| | | Cough | 1 | 0 | 0 |
| | | Respiratory failure | 1 | 0 | 0 |
| | | Respiratory, thoracic and mediastinal disorders | 13 | 1 | 8 |
| | Skin and subcutaneous tissue disorders | Angioedema | 1 | 0 | 1 |
| | | Urticaria | 5 | 0 | 5 |
| | | Swelling face | 2 | 0 | 2 |

 Outcome Description


 (Causality possible,Causality probable,Causality certain)

 Suspect Type

 Suspect Code

 Case Group

 GM

 Flupenthixol Decanoate

Medicine summary - Antipsychotics- flupenthixol

| | | | Case Group | Death Outcomes | Sole | |
|----------------|----------------------------------------|-----------------------------------------------|------------|----------------|-----------|------------|
| Reaction Count | Skin and subcutaneous tissue disorders | Rash erythematous | 5 | 0 | 4 | |
| | | Pruritus | 7 | 0 | 6 | |
| | | Rash | 3 | 0 | 1 | |
| | | Rash generalised | 1 | 0 | 0 | |
| | | Rash maculo-papular | 2 | 0 | 1 | |
| | | Skin ulcer | 1 | 0 | 1 | |
| | | Acne | 1 | 0 | 1 | |
| | | Hyperhidrosis | 1 | 0 | 0 | |
| | | Skin and subcutaneous tissue disorders | 29 | 0 | 22 | |
| | Social circumstances | Treatment noncompliance | 1 | 0 | 0 | |
| | | Life expectancy shortened | 1 | 0 | 1 | |
| | | Social circumstances | 2 | 0 | 1 | |
| | Vascular disorders | Circulatory collapse | 1 | 0 | 0 | |
| | | Hypotension | 1 | 0 | 1 | |
| | | Deep vein thrombosis | 2 | 1 | 0 | |
| | | Hypertension | 2 | 0 | 1 | |
| | | Vascular disorders | 6 | 1 | 2 | |
| | Reaction | | | 266 | 5 | 175 |

 Rows are suppressed based on zeros and empty cells for Case Group

 Outcome Description


 (Causality possible,Causality probable,Causality certain)

 Suspect Type

 Suspect Code

 Case Group

 GM

 Flupenthixol Decanoate